BridgeMD
New treatment option for Early Gastric Cancer
Official title The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
ClinicalTrials.gov ID: NCT05323929
What this study is testing
- What it's testing
- This study is a single-center, prospective, group-controlled clinical trial, aiming to clarify the relationship between the depth of dissection and scar formation in the treatment of early gastric cancer by ESD, and to provide high-quality evidence-based medicine for the treatment of early gastric cancer.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patients older than 18 years old and younger than 75 years old.
- Early gastric cancer (T1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (T1a stage)...
- Pathological diagnosis of gastric cancer.
- No further treatment is required.
- Patients diagnosed for the first time without other serious gastrointestinal diseases.
You likely can't join if
- Those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment.
- Advanced gastric cancer; or undifferentiated gastric cancer lesions \> 2 cm in diameter; or differentiated gastric cancer with ulcer lesions \> 3 cm...
- Coagulation disorders.
- Serious heart, liver, kidney and other diseases, can not tolerate ESD treatment.
- Patients with gastric cancer complications such as gastrointestinal bleeding and perforation that need emergency treatment.
- Patients with distant metastasis.
See the full eligibility criteria
- Patients older than 18 years old and younger than 75 years old.
- Early gastric cancer (T1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (T1a stage), differentiated with ulcer, lesion diameter \<3cm; or early gastric cancer...
- Pathological diagnosis of gastric cancer.
- No further treatment is required.
- Patients diagnosed for the first time without other serious gastrointestinal diseases.
- Those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment.
- Advanced gastric cancer; or undifferentiated gastric cancer lesions \> 2 cm in diameter; or differentiated gastric cancer with ulcer lesions \> 3 cm in diameter.
- Coagulation disorders.
- Serious heart, liver, kidney and other diseases, can not tolerate ESD treatment.
- Patients with gastric cancer complications such as gastrointestinal bleeding and perforation that need emergency treatment.
- Patients with distant metastasis.
- Patients with other tumors, patients with a history of malignant tumors (except early carcinoma in situ.
- The patient himself requests to withdraw from the trial.
- The researcher believes that the patient is not suitable to participate in this study.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.